See the DrugPatentWatch profile for lurbinectedin

Delayed side effects after lurbinectedin treatment can occur, but the specific timeline is not explicitly stated in the available information. Lurbinectedin is a novel anticancer drug that has been approved for the treatment of certain types of cancer [1]. The drug functions by inhibiting the transcriptional activity of oncogenic fusion proteins [1].

Clinical trials have reported various side effects associated with lurbinectedin, including neutropenia, diarrhea, nausea, fatigue, and increased liver enzymes [1]. However, the timing of these side effects and whether they can occur after treatment has ceased is not explicitly mentioned in the available information.

It is important to note that delayed side effects can occur with many cancer treatments, including chemotherapy and targeted therapies [2]. These side effects can be caused by damage to healthy cells and tissues, as well as by the body's immune response to treatment [2]. Delayed side effects can occur weeks, months, or even years after treatment has ended [2].

Patients who have received lurbinectedin treatment should be monitored for side effects and should report any new or worsening symptoms to their healthcare provider [1]. Healthcare providers should be aware of the potential for delayed side effects and should provide appropriate monitoring and management [2].

In summary, delayed side effects can occur after lurbinectedin treatment, but the specific timeline is not explicitly stated in the available information. Patients should be monitored for side effects and should report any new or worsening symptoms to their healthcare provider.

Sources:
[1] DrugPatentWatch.com. (2021). Lurbinectedin. Retrieved from <https://www.drugpatentwatch.com/drugs/lurbinectedin>.
[2] National Cancer Institute. (2021). Delayed Effects of Cancer Treatment. Retrieved from <https://www.cancer.gov/about-cancer/treatment/side-effects/late-effects>.